Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths

Biotech stocks Nuvalent and Iteos diverged Monday on updates for their lung cancer treatments at the ESMO meeting in Madrid.

Investors Business Daily

Bausch Reportedly Explores A Sale; Could Alcon, J&J Or AbbVie Buy It?

Bausch + Lomb stock surged Monday — briefly breaking out — on a report the company is working with advisors to explore a potential sale.

Investors Business Daily

Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug

Ascendis Pharma stock rocketed Monday on promising test results for a growth treatment that could rival BioMarin's approved drug, Voxzogo.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Gilead’s biannual HIV shot reduced risk of infections by 96 percent, company says

The drugmaker said its injections were 89 percent more effective than its own Truvada

The Independent UK

Moderna's Pain Continues Amid Flurry Of Downgrades Following 'Tough' R&D Day

Moderna stock tumbled again Friday on a series of downgrades and price-target cuts following a "tough update" at its R&D Day.

Investors Business Daily

Gilead Sciences Pops On A New $4 Billion Opportunity In HIV Prevention

Gilead stock popped Thursday after the biotech giant said its twice-yearly shot prevented 99.9% of HIV infections in a study.

Investors Business Daily

Moderna Stock Plunges as Vaccine Maker Slashes R&D Budget: What to Know

Moderna stock is plunging Thursday after the COVID-19 vaccine maker announced plans to drastically cut its R&D spending to focus on new product approvals.

Kiplinger

Read news from The Economist, FT, and more,
with one subscription

Summit Therapeutics, With 85% Gain This Week, Rockets Again On $235 Million Sale

Summit Therapeutics stock rocketed again Thursday — adding onto an 85% gain this week — after raising $235 million in a private placement.

Investors Business Daily

J&J CEO Slams Biden's Drug Pricing Law, Says It Will 'Chill' Innovation

J&J CEO explained that the new drug-price negotiation law threatens development of new drugs, according to Bloomberg.

International Business Times

Moderna Crashes After Slashing Its R&D Budget, Issuing Light Guidance

Moderna stock crashed Thursday after the Covid vaccine maker slashed its R&D budget and issued a light sales view.

Investors Business Daily

Biotech Stock Near Buy Point Amid Impressive Sales Track Record

Rhythm Pharmaceuticals is near a buy point after strong sales in the second quarter.

Investors Business Daily

British company deliberately hiked price of life-saving drug, court rules

The NHS was forced to spend over £80m a year on hydrocortisone tablets after the price was rigged

The Independent UK

Travere Stock Pops After Snagging Full Approval For Calliditas Rival In Kidney Disease

Travere Therapeutics stock surged Friday after the biotech company snagged full FDA approval for its kidney disease treatment, Filspari.

Investors Business Daily

Patient warning over plan to ease GP load with pharmacy

The peak body for GPs has hit out at a NSW government plan to let pharmacies treat more health conditions to take pressure off doctors.

AAP

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Undervalued Healthcare Stocks With Strong Upside Potential

The healthcare sector is set for robust growth, driven by surging demand for quality treatments, a growing patient base, breakthroughs in biopharma, and supportive policies. Therefore, investors could consider undervalued pharmaceutical stocks like Merck & Co. (MRK), Pfizer (PFE), and Cigna (CI) with significant upside potential. Read more.

The Independent UK

5 takeaways from AP's report on the big backlog of uninspected drug factories

Nearly five years after COVID-19, a new analysis by The Associated Press shows that U.S. regulators are struggling to address a massive backlog of uninspected pharmaceutical plants

The Independent UK

Nearly 2,000 drug manufacturing plants are overdue for FDA inspections after COVID delays, AP finds

U.S. health inspectors are still struggling to address a massive backlog of pharmaceutical plants that went uninspected during disruptions caused by COVID-19

Investors Business Daily

How Lilly, Novo Could Beat Tesla To The Trillion-Dollar Club; Plus, Nvidia's Battle With Microsoft, Apple

Weight-loss drug kingpins Eli Lilly and Novo Nordisk could join the trillion-dollar company club before even Tesla, according to a report.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Shares Dive On C-Suite Changes

Dyne Therapeutics stock crashed Tuesday after several key executives departed on the heels of what the company calls "unprecedented" in DMD.

Top News

Florida Transit Agency Introduces Narcan Kits To Combat Overdoses

Pinellas Suncoast Transit Authority in Florida takes proactive steps to address opioid crisis by training employees and installing Narcan kits at terminals.

Tom’s Hardware

Another Radeon RX 8000 GPU spotted in transit — Navi 44 XL GPU hints that RDNA 4 may mimic RDNA in product segmentation

The lifecycle of AMD's new (but still unannounced) GPU continues, and now we're seeing the low-end version move in shipping manifests.

Investors Business Daily

S&P 500 Giants Meta, Eli Lilly Lead 5 Stocks Near Buy Points

Meta, Costco and Eli Lilly along with two others are trading near buy points coming out of a week marked by Nvidia earnings.

Investors Business Daily

The 10 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race

The weight-loss drugs market could be worth up to $144 billion within six years. And a bevy of pharma stocks could get a lift.

StockNews.com

3 Oncology Stocks With Major Upside

With the rising prevalence of chronic diseases, increasing cell and gene therapies, and rising tech adoption in the biotech industry, the oncology market is booming. Amid this backdrop, investors could consider quality biotech stocks Pyxis Oncology (PYXS), Immatics (IMTX), and Jazz Pharmaceuticals (JAZZ), having significant upside potential. Continue reading.

Investors Business Daily

Why This Rival To Gilead, Novartis Just Jumped 10% — And Why There Are Caveats

Galapagos stock surged Monday after the Food and Drug Administration cleared the biotech company to begin testing its cancer drug in people.

1 … 10 11 12 13

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations